With the conceptual advance about four decades ago that type 1 diabetes represents an
autoimmune disease, hope arose that immune-based therapies would soon emerge to …

Type 1 diabetes is an autoimmune disease with onset from early childhood. The insulin-
producing pancreatic beta cells are destroyed by CD8+ cytotoxic T cells. The disease is …

For more than 35 years, the NOD mouse has been the primary animal model for studying
autoimmune diabetes. During this time, striking similarities to the human disease have been …

Immunologically based clinical trials performed thus far have failed to cure type 1 diabetes
(T1D), in part because these approaches were nonspecific. Because the disease is driven …

Despite the benefit of insulin, blockade of autoimmune attack and regeneration of pancreatic
islets are ultimate goals for the complete cure of type 1 diabetes (T1D). Long-term …

It has been 100 years since the life-saving discovery of insulin, yet daily management of type
1 diabetes (T1D) remains challenging. Even with closed-loop systems, the prevailing need …

Recent advances in immunotherapeutics have not yet changed the routine management of
autoimmune type 1 diabetes. There is an opportunity to repurpose therapeutics used to treat …

The role of the NLRP3 inflammasome is pivotal in the pathophysiology and progression of
diabetes mellitus (DM), encompassing both type 1 (T1D), or type 2 (T2D). As part of the …

Immune therapeutics holds great promise in the treatment of type 1 diabetes (T1D).
Nonetheless, their progress is hampered by limited efficacy, equipoise, or issues of safety …

There is a growing understanding that the early phases of type 1 diabetes (T1D) are
characterised by a deleterious dialogue between the pancreatic beta cells and the immune …